Merck & Co., Inc. $MRK Position Reduced by Brown Shipley& Co Ltd

Key Points

• Brown Shipley & Co. reduced its Merck stake by 20% in the third quarter, selling 7,331 shares and retaining 29,398 shares valued at approximately $4.27 million. Institutional investors collectively own 76.07% of Merck.
• Merck shares recently traded at $145.81, near the upper end of their 52-week range, while the company reported quarterly revenue of $16.61 billion that exceeded estimates. Merck also pays an annualized dividend of $3.40 per share, yielding about 2.3%.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $151.32. However, investors face risks from upcoming generic competition, patent expirations, and litigation affecting a subcutaneous Keytruda formulation in Europe.

Brown Shipley& Co Ltd decreased its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 20.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,398 shares of the company's stock after selling 7,331 shares during the period. Merck & Co., Inc. accounts for about 2.1% of Brown Shipley& Co Ltd's holdings, making the stock its 15th largest holding. Brown Shipley& Co Ltd's holdings in Merck & Co., Inc. were worth $4,272,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Inspirion Wealth Advisors LLC purchased a new position in Merck & Co., Inc. during the third quarter valued at approximately $240,000. Eclectic Associates Inc. ADV purchased a new position in shares of Merck & Co., Inc. during the third quarter worth $301,000. LifeGoal Investments LLC acquired a new position in shares of Merck & Co., Inc. in the 3rd quarter valued at about $221,000. Market Street Wealth Management Advisors LLC purchased a new stake in shares of Merck & Co., Inc. during the 3rd quarter worth about $200,000. Finally, Monument Capital Management grew its holdings in Merck & Co., Inc. by 0.7% in the third quarter. Monument Capital Management now owns 22,830 shares of the company's stock valued at $3,317,000 after purchasing an additional 165 shares during the period. Hedge funds and other institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Price Performance

MRK traded up $3.43 during trading on Friday, reaching $145.81. The stock had a trading volume of 3,216,070 shares, compared to its average volume of 10,622,946. Merck & Co., Inc. has a 1-year low of $82.01 and a 1-year high of $156.92. The firm has a market capitalization of $359.75 billion, a price-to-earnings ratio of 116.63, a price-to-earnings-growth ratio of 6.42 and a beta of 0.21. The stock has a 50 day moving average of $143.59 and a two-hundred day moving average of $128.16. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The company's revenue was up 5.1% compared to the same quarter last year. During the same period last year, the company posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 2.67 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were given a dividend of $0.85 per share. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. Merck & Co., Inc.'s payout ratio is currently 272.00%.

Insider Buying and Selling

In related news, EVP David Williams sold 52,847 shares of the company's stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the transaction, the executive vice president directly owned 31,716 shares in the company, valued at $4,084,069.32. This represents a 62.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Richard Deluca sold 11,699 shares of the company's stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total value of $1,539,939.37. Following the completion of the transaction, the executive vice president owned 110,167 shares of the company's stock, valued at $14,501,282.21. The trade was a 9.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 228,238 shares of company stock valued at $29,977,783 in the last quarter. Insiders own 0.17% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on MRK shares. Daiwa Securities Group raised shares of Merck & Co., Inc. from a "neutral" rating to an "outperform" rating and set a $143.00 price objective for the company in a report on Wednesday, August 12th. Sanford C. Bernstein increased their price objective on Merck & Co., Inc. from $100.00 to $105.00 and gave the stock a "market perform" rating in a research report on Tuesday, August 4th. JPMorgan Chase & Co. increased their target price on shares of Merck & Co., Inc. from $150.00 to $165.00 and gave the company an "overweight" rating in a report on Monday. Scotiabank raised their price target on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the stock a "sector outperform" rating in a research note on Tuesday, September 29th. Finally, Wells Fargo & Company upped their price objective on Merck & Co., Inc. from $150.00 to $170.00 and gave the stock an "overweight" rating in a report on Friday, September 4th. Seventeen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of "Moderate Buy" and an average target price of $151.32.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approved WELIREG plus LENVIMA for adults with advanced renal cell carcinoma previously treated with PD-1/PD-L1 therapy. The decision expands Merck’s commercial oncology portfolio and could provide an additional growth opportunity alongside Keytruda. Merck also started a first-in-human trial using Cyprumed’s oral peptide-delivery platform, adding a potentially valuable pipeline program. Merck Wins FDA Approval for WELIREG Plus LENVIMA
• Positive Sentiment: Cantor Fitzgerald raised its Merck price target to $145 from $120, while maintaining a neutral rating. The higher target reflects improved valuation support, although it implies limited upside at recent trading levels. Cantor Fitzgerald Raises Pharma Price Targets
• Neutral Sentiment: Analyst views remain divided: Morgan Stanley issued a buy rating in one report, while a separate report highlighted a pessimistic forecast. The conflicting outlooks suggest that Merck’s current valuation and future growth profile remain debated. Morgan Stanley Gives Merck a Buy Rating
• Neutral Sentiment: Apella Capital increased its Merck position by 16.6% to 43,902 shares. The purchase indicates institutional confidence, but the relatively small holding is unlikely to materially affect the company’s fundamentals. Apella Capital Increases Merck Stake
• Negative Sentiment: A Dutch court blocked Merck’s subcutaneous Keytruda from being sold in eight European markets after Halozyme won an injunction in a patent dispute. The ruling could delay or restrict a potentially important, more convenient Keytruda formulation and increase litigation risk. Halozyme Wins Court Order Blocking Keytruda SC in Europe
• Negative Sentiment: Industry analysts identify Merck as one of the pharmaceutical companies most exposed to near-term generic competition as major patents expire. That patent-cliff risk could pressure revenue and earnings growth beyond the current period. Pharma Patent Cliff Risks

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.